Inozyme Pharma Analyst Ratings
Inozyme Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 09/08/2023 | 234.08% | Wedbush | → $15 | Maintains | Outperform |
| 08/09/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 08/08/2023 | 256.35% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 08/04/2023 | 256.35% | HC Wainwright & Co. | $19 → $16 | Maintains | Buy |
| 07/27/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 05/10/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 04/19/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 03/23/2023 | 33.63% | Jefferies | $4.5 → $6 | Upgrades | Hold → Buy |
| 03/23/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 02/17/2023 | 345.43% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 05/26/2022 | 11.36% | Jefferies | → $5 | Initiates Coverage On | → Hold |
| 05/11/2022 | 345.43% | HC Wainwright & Co. | $33 → $20 | Maintains | Buy |
| 03/16/2022 | 456.79% | Wedbush | $35 → $25 | Maintains | Outperform |
| 02/07/2022 | 634.97% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 11/29/2021 | 412.25% | Needham | → $23 | Initiates Coverage On | → Buy |
| 08/18/2020 | 679.51% | Wedbush | → $35 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 634.97% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 08/18/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/18/2020 | 790.87% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/27/2023 | 412.25% | 李约瑟 | →$23 | 重申 | 购买→购买 |
| 09/08/2023 | 234.08% | 韦德布什 | →$15 | 维护 | 跑赢大盘 |
| 08/09/2023 | 412.25% | 李约瑟 | →$23 | 重申 | 购买→购买 |
| 2023/08/08 | 256.35% | HC Wainwright公司 | →$16 | 重申 | 购买→购买 |
| 08/04/2023 | 256.35% | HC Wainwright公司 | $19→$16 | 维护 | 买 |
| 07/27/2023 | 412.25% | 李约瑟 | →$23 | 重申 | 购买→购买 |
| 2023年05月10日 | 412.25% | 李约瑟 | →$23 | 重申 | →购买 |
| 04/19/2023 | 412.25% | 李约瑟 | →$23 | 重申 | →购买 |
| 03/23/2023 | 33.63% | 杰富瑞 | $4.5→$6 | 升级 | 持有→购买 |
| 03/23/2023 | 412.25% | 李约瑟 | →$23 | 重申 | →购买 |
| 02/17/2023 | 345.43% | HC Wainwright公司 | →$20 | 重申 | →购买 |
| 02/17/2023 | 412.25% | 李约瑟 | →$23 | 重申 | →购买 |
| 2022年05月26日 | 11.36% | 杰富瑞 | →$5 | 开始承保 | →保留 |
| 2022年05月11日 | 345.43% | HC Wainwright公司 | $33→$20 | 维护 | 买 |
| 03/16/2022 | 456.79% | 韦德布什 | $35→$25 | 维护 | 跑赢大盘 |
| 02/07/2022 | 634.97% | HC Wainwright公司 | →$33 | 开始承保 | →购买 |
| 2021年11月29日 | 412.25% | 李约瑟 | →$23 | 开始承保 | →购买 |
| 2020/08/18 | 679.51% | 韦德布什 | →$35 | 开始承保 | →跑赢大盘 |
| 2020/08/18 | 634.97% | B of A证券 | →$33 | 开始承保 | →购买 |
| 2020/08/18 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 2020/08/18 | 790.87% | 派珀·桑德勒 | →$40 | 开始承保 | →超重 |
What is the target price for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的目标价是多少？
The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Needham on September 27, 2023. The analyst firm set a price target for $23.00 expecting INZY to rise to within 12 months (a possible 412.25% upside). 12 analyst firms have reported ratings in the last year.
Needham于2023年9月27日报道了Inozyme制药公司(纳斯达克代码：INZY)的最新目标价。这家分析公司将Inzy的目标价定为23美元，预计Inzy将在12个月内上涨(涨幅可能为412.25%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的最新分析师评级是多少？
The latest analyst rating for Inozyme Pharma (NASDAQ: INZY) was provided by Needham, and Inozyme Pharma reiterated their buy rating.
Needham提供了对Inozyme Pharma(纳斯达克股票代码：INZY)的最新分析师评级，Inozyme Pharma重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?
Inozyme Pharma(Inzy)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Inozyme Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Inozyme Pharma的上一次评级是在2023年9月27日提交的，因此您应该预计下一次评级将在2024年9月27日左右提供。
Is the Analyst Rating Inozyme Pharma (INZY) correct?
分析师对Inozyme Pharma(Inzy)的评级正确吗？
While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a reiterated with a price target of $0.00 to $23.00. The current price Inozyme Pharma (INZY) is trading at is $4.49, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但Inozyme Pharma(Inzy)的最新评级重申了目标价在0.00美元至23.00美元之间。Inozyme Pharma(Inzy)目前的交易价格为4.49美元，在分析师的预测区间内。
译文内容由第三方软件翻译。